Literature DB >> 32920979

Downregulation of miR-326 and its host gene β-arrestin1 induces pro-survival activity of E2F1 and promotes medulloblastoma growth.

Evelina Miele1, Agnese Po2, Angela Mastronuzzi1, Andrea Carai3, Zein Mersini Besharat4, Natalia Pediconi5, Luana Abballe4, Giuseppina Catanzaro4, Claudia Sabato4, Enrico De Smaele4, Gianluca Canettieri2, Lucia Di Marcotullio2, Alessandra Vacca4, Antonello Mai6, Massimo Levrero7,8, Stefan M Pfister9,10,11, Marcel Kool9,11, Felice Giangaspero12,13, Franco Locatelli1,14, Elisabetta Ferretti4.   

Abstract

Persistent mortality rates of medulloblastoma (MB) and severe side effects of the current therapies require the definition of the molecular mechanisms that contribute to tumor progression. Using cultured MB cancer stem cells and xenograft tumors generated in mice, we show that low expression of miR-326 and its host gene β-arrestin1 (ARRB1) promotes tumor growth enhancing the E2F1 pro-survival function. Our models revealed that miR-326 and ARRB1 are controlled by a bivalent domain, since the H3K27me3 repressive mark is found at their regulatory region together with the activation-associated H3K4me3 mark. High levels of EZH2, a feature of MB, are responsible for the presence of H3K27me3. Ectopic expression of miR-326 and ARRB1 provides hints into how their low levels regulate E2F1 activity. MiR-326 targets E2F1 mRNA, thereby reducing its protein levels; ARRB1, triggering E2F1 acetylation, reverses its function into pro-apoptotic activity. Similar to miR-326 and ARRB1 overexpression, we also show that EZH2 inhibition restores miR-326/ARRB1 expression, limiting E2F1 pro-proliferative activity. Our results reveal a new regulatory molecular axis critical for MB progression.
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Entities:  

Keywords:  ARRB1; E2F1; EZH2; medulloblastoma; miR-326

Mesh:

Substances:

Year:  2020        PMID: 32920979      PMCID: PMC7858128          DOI: 10.1002/1878-0261.12800

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   7.449


  85 in total

1.  Clinical significance of Polycomb gene expression in brain tumors.

Authors:  Francesco Crea; Elaine M Hurt; William L Farrar
Journal:  Mol Cancer       Date:  2010-09-30       Impact factor: 27.401

2.  A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription.

Authors:  Jiuhong Kang; Yufeng Shi; Bin Xiang; Bin Qu; Wenjuan Su; Min Zhu; Min Zhang; Guobin Bao; Feifei Wang; Xiaoqing Zhang; Rongxi Yang; Fengjuan Fan; Xiaoqing Chen; Gang Pei; Lan Ma
Journal:  Cell       Date:  2005-12-02       Impact factor: 41.582

Review 3.  Medulloblastoma.

Authors:  Paul A Northcott; Giles W Robinson; Christian P Kratz; Donald J Mabbott; Scott L Pomeroy; Steven C Clifford; Stefan Rutkowski; David W Ellison; David Malkin; Michael D Taylor; Amar Gajjar; Stefan M Pfister
Journal:  Nat Rev Dis Primers       Date:  2019-02-14       Impact factor: 52.329

4.  Intertumoral Heterogeneity within Medulloblastoma Subgroups.

Authors:  Florence M G Cavalli; Marc Remke; Ladislav Rampasek; John Peacock; David J H Shih; Betty Luu; Livia Garzia; Jonathon Torchia; Carolina Nor; A Sorana Morrissy; Sameer Agnihotri; Yuan Yao Thompson; Claudia M Kuzan-Fischer; Hamza Farooq; Keren Isaev; Craig Daniels; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee; Wieslawa A Grajkowska; Marta Perek-Polnik; Alexandre Vasiljevic; Cecile Faure-Conter; Anne Jouvet; Caterina Giannini; Amulya A Nageswara Rao; Kay Ka Wai Li; Ho-Keung Ng; Charles G Eberhart; Ian F Pollack; Ronald L Hamilton; G Yancey Gillespie; James M Olson; Sarah Leary; William A Weiss; Boleslaw Lach; Lola B Chambless; Reid C Thompson; Michael K Cooper; Rajeev Vibhakar; Peter Hauser; Marie-Lise C van Veelen; Johan M Kros; Pim J French; Young Shin Ra; Toshihiro Kumabe; Enrique López-Aguilar; Karel Zitterbart; Jaroslav Sterba; Gaetano Finocchiaro; Maura Massimino; Erwin G Van Meir; Satoru Osuka; Tomoko Shofuda; Almos Klekner; Massimo Zollo; Jeffrey R Leonard; Joshua B Rubin; Nada Jabado; Steffen Albrecht; Jaume Mora; Timothy E Van Meter; Shin Jung; Andrew S Moore; Andrew R Hallahan; Jennifer A Chan; Daniela P C Tirapelli; Carlos G Carlotti; Maryam Fouladi; José Pimentel; Claudia C Faria; Ali G Saad; Luca Massimi; Linda M Liau; Helen Wheeler; Hideo Nakamura; Samer K Elbabaa; Mario Perezpeña-Diazconti; Fernando Chico Ponce de León; Shenandoah Robinson; Michal Zapotocky; Alvaro Lassaletta; Annie Huang; Cynthia E Hawkins; Uri Tabori; Eric Bouffet; Ute Bartels; Peter B Dirks; James T Rutka; Gary D Bader; Jüri Reimand; Anna Goldenberg; Vijay Ramaswamy; Michael D Taylor
Journal:  Cancer Cell       Date:  2017-06-12       Impact factor: 31.743

5.  Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon.

Authors:  V Tropepe; M Sibilia; B G Ciruna; J Rossant; E F Wagner; D van der Kooy
Journal:  Dev Biol       Date:  1999-04-01       Impact factor: 3.582

Review 6.  Targeting EZH2 in cancer.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Nat Med       Date:  2016-02       Impact factor: 53.440

7.  Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.

Authors:  Adrian M Dubuc; Marc Remke; Andrey Korshunov; Paul A Northcott; Shing H Zhan; Maria Mendez-Lago; Marcel Kool; David T W Jones; Alexander Unterberger; A Sorana Morrissy; David Shih; John Peacock; Vijay Ramaswamy; Adi Rolider; Xin Wang; Hendrik Witt; Thomas Hielscher; Cynthia Hawkins; Rajeev Vibhakar; Sidney Croul; James T Rutka; William A Weiss; Steven J M Jones; Charles G Eberhart; Marco A Marra; Stefan M Pfister; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2012-11-25       Impact factor: 17.088

8.  Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples.

Authors:  Paul A Northcott; David J H Shih; Marc Remke; Yoon-Jae Cho; Marcel Kool; Cynthia Hawkins; Charles G Eberhart; Adrian Dubuc; Toumy Guettouche; Yoslayma Cardentey; Eric Bouffet; Scott L Pomeroy; Marco Marra; David Malkin; James T Rutka; Andrey Korshunov; Stefan Pfister; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2011-11-06       Impact factor: 17.088

9.  Modeling medulloblastoma in vivo and with human cerebellar organoids.

Authors:  Claudio Ballabio; Marica Anderle; Matteo Gianesello; Chiara Lago; Evelina Miele; Marina Cardano; Giuseppe Aiello; Silvano Piazza; Davide Caron; Francesca Gianno; Andrea Ciolfi; Lucia Pedace; Angela Mastronuzzi; Marco Tartaglia; Franco Locatelli; Elisabetta Ferretti; Felice Giangaspero; Luca Tiberi
Journal:  Nat Commun       Date:  2020-01-29       Impact factor: 14.919

10.  Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer.

Authors:  Vincent Zecchini; Basetti Madhu; Roslin Russell; Nelma Pértega-Gomes; Anne Warren; Edoardo Gaude; Joana Borlido; Rory Stark; Heather Ireland-Zecchini; Roheet Rao; Helen Scott; Joan Boren; Charlie Massie; Mohammad Asim; Kevin Brindle; John Griffiths; Christian Frezza; David E Neal; Ian G Mills
Journal:  EMBO J       Date:  2014-05-16       Impact factor: 11.598

View more
  2 in total

1.  Long noncoding RNA FAM225A promotes the malignant progression of gastric cancer through the miR-326/PADI2 axis.

Authors:  Xiang Ma; Gang Wang; Hao Fan; Zengliang Li; Wangwang Chen; Jian Xiao; Peidong Ni; Kanghui Liu; Kuan Shen; Yuanhang Wang; Zekuan Xu; Li Yang
Journal:  Cell Death Discov       Date:  2022-01-11

Review 2.  The long and short non-coding RNAs modulating EZH2 signaling in cancer.

Authors:  Sepideh Mirzaei; Mohammad Hossein Gholami; Kiavash Hushmandi; Farid Hashemi; Amirhossein Zabolian; Israel Canadas; Ali Zarrabi; Noushin Nabavi; Amir Reza Aref; Francesco Crea; Yuzhuo Wang; Milad Ashrafizadeh; Alan Prem Kumar
Journal:  J Hematol Oncol       Date:  2022-03-02       Impact factor: 17.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.